Cargando…

Real-World Persistency for Inflammatory Bowel Disease Biologics Using Patient Registry Data

BACKGROUND: Although it is a truism that drugs benefit patients only when taken, surprisingly little is known about real-world drug-use persistence and discontinuation, even for expensive biologic drugs. METHODS: We used longitudinal self-reported drug-use data from the inflammatory bowel disease (I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goss Sawhney, Tia, Dobes, Angela, O’Charoen, Sirimon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Observations and Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629214/ https://www.ncbi.nlm.nih.gov/pubmed/37941597 http://dx.doi.org/10.1093/crocol/otad051

Ejemplares similares

QALYs: The Math Doesn’t Work
por: Sawhney, Tia G., et al.
Publicado: (2023)

Real-world data on the infliximab biosimilar CT-P13 (Remsima(®)) in inflammatory bowel disease
por: Huguet, Jose María, et al.
Publicado: (2021)

Real-World Treatment Patterns and Physician Preferences for Biologics in Moderate-to-Severe Inflammatory Bowel Disease: Retrospective Chart Review in Europe
por: Huynh, Lynn, et al.
Publicado: (2022)

Persistence With Biologic Therapy and Associated Costs of Patients With Inflammatory Bowel Disease: A German Retrospective Claims Data Analysis
por: Mahlich, Joerg, et al.
Publicado: (2021)

Comparative risk of infections among real-world users of biologics for juvenile idiopathic arthritis: data from the German BIKER registry
por: Thiele, Franz, et al.
Publicado: (2021)

The Real-World Global Use of Patient-Reported Outcomes for the Care of Patients With Inflammatory Bowel Disease
por: Horrigan, Jamie M, et al.
Publicado: (2023)

Real-world disease activity and sociodemographic, clinical and treatment characteristics of moderate-to-severe inflammatory bowel disease in Brazil
por: Zaltman, Cyrla, et al.
Publicado: (2021)

Real-World Effectiveness of Vedolizumab Dose Escalation in Patients With Inflammatory Bowel Disease: A Systematic Literature Review
por: Patel, Dipen, et al.
Publicado: (2022)

Methodology and Initial Results From a Real-World Observational Cohort of Patients With Inflammatory Bowel Disease: TARGET-IBD
por: Click, Benjamin, et al.
Publicado: (2021)

Risks of Development of COVID-19 Among Patients With Inflammatory Bowel Disease: A Comparative Assessment of Risk Factors for Incident Infection
por: Long, Millie D, et al.
Publicado: (2022)

Persistence on biologic DMARD monotherapy after achieving rheumatoid arthritis disease control on combination therapy: retrospective analysis of corrona registry data
por: Pappas, Dimitrios A., et al.
Publicado: (2020)

Extraintestinal Manifestations of Inflammatory Bowel Disease Are Associated With Increased Biologic Cycling
por: Alizadeh, Madeline, et al.
Publicado: (2023)

Favorable Outcomes Combining Vedolizumab With Other Biologics or Tofacitinib for Treatment of Inflammatory Bowel Disease
por: Llano, Ernesto M, et al.
Publicado: (2021)

Adverse Drug Reactions from Real-World Data in Inflammatory Bowel Disease Patients in the IBDREAM Registry
por: Giraud, Eline L., et al.
Publicado: (2021)

Disease Burden and Patient-Reported Outcomes Among Ulcerative Colitis Patients According to Therapy at Enrollment Into CorEvitas’ Inflammatory Bowel Disease Registry
por: Cross, Raymond K, et al.
Publicado: (2022)

Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease
por: Alayo, Quazim A, et al.
Publicado: (2022)

The Use and Efficacy of Biological Therapies for Inflammatory Bowel Disease in a Danish Tertiary Centre 2010–2020
por: Wewer, Mads Damsgaard, et al.
Publicado: (2022)

Contemporary characteristics, management, and outcomes of patients hospitalized for atrial fibrillation in China: results from the real-world study of Chinese atrial fibrillation registry
por: Zhao, Qing-Yan, et al.
Publicado: (2020)

Fecal Incontinence in Inflammatory Bowel Disease
por: Kamal, Natasha, et al.
Publicado: (2021)

Incidence of Adverse Psychiatric Events During Treatment of Inflammatory Bowel Disease With Biologic Therapies: A Systematic Review
por: Jain, Avni, et al.
Publicado: (2019)

Overuse of Tuberculosis Surveillance Testing in Patients With Inflammatory Bowel Disease Compared to Non-IBD Patients on Biologic Therapy
por: Fine, Sean, et al.
Publicado: (2021)

Using real world data to assess cardiovascular outcomes of two antidiabetic treatment classes
por: Stapff, Manfred Paul
Publicado: (2018)

Retrospective Cohort Study Comparing Infliximab-dyyb and Infliximab in Biologic-Naive Patients With Inflammatory Bowel Disease in the United States
por: Smith, Joshua T, et al.
Publicado: (2021)

Association Between Inflammatory Bowel Disease and Pruritus
por: Iwamoto, Shiho, et al.
Publicado: (2020)

Opioid Use in Patients With Inflammatory Bowel Disease
por: Lin, Xiwu, et al.
Publicado: (2020)

Economic Burden of Fatigue in Inflammatory Bowel Disease
por: Ananthakrishnan, Ashwin N, et al.
Publicado: (2023)

Natural Transmission of Helicobacter saguini Causes Multigenerational Inflammatory Bowel Disease in C57/129 IL-10(−/−) Mice
por: Mannion, Anthony, et al.
Publicado: (2020)

Fatigue in patients with inflammatory bowel disease in Eastern China
por: Gong, Shan-Shan, et al.
Publicado: (2021)

Urotensin II levels in patients with inflammatory bowel disease
por: Alicic, Damir, et al.
Publicado: (2021)

Hospitalizations and in-hospital mortality for inflammatory bowel disease in Brazil
por: Guedes, Ana Luiza Vilar, et al.
Publicado: (2022)

Tofacitinib Adherence and Outcomes in Refractory Inflammatory Bowel Disease
por: Wiles, C Alex, et al.
Publicado: (2021)

The beneficial effect of csDMARDs co-medication on drug persistence of first-line TNF inhibitor in rheumatoid arthritis patients: data from Czech ATTRA registry
por: Skácelová, Martina, et al.
Publicado: (2022)

Comparative study between bowel ultrasound and magnetic resonance enterography among Egyptian inflammatory bowel disease patients
por: Kamel, Shimaa, et al.
Publicado: (2020)

HLA-DQ: Celiac disease vs inflammatory bowel disease
por: Bosca-Watts, Marta Maia, et al.
Publicado: (2018)

Disease impact on the quality of life of children with inflammatory bowel disease
por: Chouliaras, Giorgos, et al.
Publicado: (2017)

Identification of Risk Factors for Coexisting Sinusitis and Inflammatory Bowel Disease
por: Rai, Victoria, et al.
Publicado: (2021)

The Impact of Inflammatory Bowel Disease Clinic On-site Vaccination Services
por: Hussain, Nadeen, et al.
Publicado: (2021)

Adherence to Inflammatory Bowel Disease Medications in Southern New Zealand
por: Aluzaite, Kristina, et al.
Publicado: (2021)

Variable outcome in infantile-onset inflammatory bowel disease in an Asian cohort
por: Lee, Way Seah, et al.
Publicado: (2016)

FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease
por: Rosenfeld, Greg, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0a2e2pgfoop6q24jlb20b3se99